Session » (2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2371

A Predictive Model Combining Clinical and Laboratory Parameters to Predict anti-TNF Response in Patients with Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 2366

Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs

10:30AM-12:30PM: Abstract Number: 2346

Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis

10:30AM-12:30PM: Abstract Number: 2358

Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 2374

Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada

10:30AM-12:30PM: Abstract Number: 2341

Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 2347

Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension

10:30AM-12:30PM: Abstract Number: 2345

Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab

10:30AM-12:30PM: Abstract Number: 2354

ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 2349

Classification of “Difficult-to-Manage Axial Spondyloarthritis”: A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time

10:30AM-12:30PM: Abstract Number: 2356

Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 2359

Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 2370

Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials

10:30AM-12:30PM: Abstract Number: 2373

Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study

10:30AM-12:30PM: Abstract Number: 2348

Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.

10:30AM-12:30PM: Abstract Number: 2376

Efficacy And Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis Stratified by Disease Course: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 2/3 Trial

10:30AM-12:30PM: Abstract Number: 2353

Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial

10:30AM-12:30PM: Abstract Number: 2344

Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)

10:30AM-12:30PM: Abstract Number: 2363

Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence

10:30AM-12:30PM: Abstract Number: 2357

Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial

10:30AM-12:30PM: Abstract Number: 2368

Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study

10:30AM-12:30PM: Abstract Number: 2355

Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors

10:30AM-12:30PM: Abstract Number: 2375

Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors

10:30AM-12:30PM: Abstract Number: 2339

Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST

10:30AM-12:30PM: Abstract Number: 2340

Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial

10:30AM-12:30PM: Abstract Number: 2362

Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial

10:30AM-12:30PM: Abstract Number: 2352

Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update

10:30AM-12:30PM: Abstract Number: 2351

Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 2350

Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 2364

Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 2342

Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe

10:30AM-12:30PM: Abstract Number: 2367

Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe

10:30AM-12:30PM: Abstract Number: 2369

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors

10:30AM-12:30PM: Abstract Number: 2338

Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India

10:30AM-12:30PM: Abstract Number: 2343

Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)

10:30AM-12:30PM: Abstract Number: 2361

Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis

10:30AM-12:30PM: Abstract Number: 2365

Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials

10:30AM-12:30PM: Abstract Number: 2360

Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data

10:30AM-12:30PM: Abstract Number: 2372

Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].